Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

October 27, 2020

Study Completion Date

October 27, 2020

Conditions
Diffuse Large B-Cell LymphomaMantle Cell LymphomaFollicular Lymphoma
Interventions
DRUG

Loncastuximab Tesirine and Durvalumab

intravenous infusion

Trial Locations (14)

10029

Icahm School of Medicine at Mount Sinai, New York

28009

Hospital General Universitario Gregorio Marañon Pabellón de Oncología, Madrid

28040

Hospital Universitario Fundación Jiménez Díaz Unidad de Limfomas Servicio de Hematologia, Madrid

32603

University of Florida Health Shands Cancer Hospital, Gainesville

33136

University of Miami - Sylvester Comprehensive Cancer Center, Miami

35294

University of Alabama at Birmingham, Birmingham

41009

Hospital Universitario Virgen Macarena Servicio Oncologia Medica, Seville

41015

Hospital Universitario Virgen Del Rocio, Seville

75246

Baylor University Medical Center, Dallas

76508

Baylor Scott & White Medical Center - Temple, Temple

79410

Joe Arrington Cancer Research and Treatment Center, Lubbock

80909

UCH-MHS Memorial Hospital Centeral, Colorado Springs

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

08036

Hospital Clinic de Barcelona, Barcelona

Sponsors
All Listed Sponsors
lead

ADC Therapeutics S.A.

INDUSTRY